If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructinga skyscraper from the top down – possible, yet at best impractical. Last week Eli Lilly and Company announced that the company’s Alzheimer’s drug solanezumab, which is intended to reduce amyloid plaque, […]

from Forbes – Tech http://ift.tt/2gIqmoa
via IFTTT